Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential tacrolimus-rituximab versus cyclical corticosteroids-cyclophosphamide in primary membranous nephropathy
NL-OMON44594Phase 3Active, not recruiting
- Sponsor
- Sociedad Española de Nefrología
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus, rituximab, cyclophosphamide, methylprednisolone and prednisolone in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Sociedad Española de Nefrología. Primary endpoint: Complete or partial remission at 24 months. Started Apr 2016; status: active, not recruiting.
02
Drugs
tacrolimusrituximabcyclophosphamidemethylprednisoloneprednisolone
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on NL-OMON44594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44594.